As Ginkgo looks to clear its name, the feds have come sniffing around on the heels of short sell report
A month and a half after a short sell attack nearly brought Ginkgo Bioworks’ newly public shares to its knees, the company on Monday took its largest step to date toward clearing its name. But it also revealed it’s currently the target of a Department of Justice probe.
Ginkgo received an “informal inquiry” from the DOJ connected to the short sell report, released last month by hedge fund Scorpion Capital, the company said during Monday’s third quarter earnings call. CEO Jason Kelly told analysts Ginkgo is “cooperating” with regulators, suggesting the investigation remains ongoing.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters